Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center

Authors :: Robert J. Motzer
Xiaoyu Jia
Susanne Velasco
Ana M. Molina
Michelle S. Ginsberg
S. Patil
Darren R. Feldman
Source :: Journal of Clinical Oncology. 29:4615-4615
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 4615 Background: Sunitinib has significant activity in pts with mRCC. We report long-term responders, defined as pts achieving ongoing complete response (CR) or remaining progression-free for > 18 ...

Full Text Access

Tools